SCIRENT Taps Cardiology Titan to Lead Medical and Safety Strategy

BERLIN – April 16, 2026 – In a strategic move poised to significantly bolster its scientific and medical capabilities, clinical research organization SCIRENT today announced the appointment of Prof. Dr. Wilhelm Haverkamp as its new Chief Medical Officer. The appointment, effective immediately, brings one of the world's foremost experts in cardiac electrophysiology into the company's leadership, signaling a deep commitment to advancing drug safety and clinical oversight in the complex field of cardiovascular medicine.

Prof. Haverkamp, who holds a professorship at the prestigious Charité – Universitätsmedizin Berlin, will leverage over three decades of clinical and scientific experience to guide SCIRENT's medical strategy. His primary focus will be on expanding the company's structured safety services, a critical component for ensuring patient well-being and data integrity in modern clinical trials.

"I am delighted to join SCIRENT and look forward to contributing my expertise to further develop innovative and high-quality drug safety services," said Prof. Haverkamp in a statement. "Ensuring patient safety and scientific excellence in clinical research is of utmost importance, and I am excited to support SCIRENT's continued growth in this field."

Fortifying the Foundations of Clinical Safety

Prof. Haverkamp’s appointment is more than a high-profile hire; it represents a deliberate fortification of the ethical and scientific bedrock of clinical research. His mandate includes the establishment and expansion of Data Safety Monitoring Committees (DSMCs) and Clinical Event Committees (CECs). These independent bodies are the gold standard in clinical trial governance, designed to provide unbiased oversight.

DSMCs are composed of independent experts who periodically review accumulating trial data to monitor for any potential harm to participants. They hold the power to recommend modifying or even halting a study, acting as a crucial safeguard. CECs, meanwhile, ensure that clinical events like heart attacks or strokes are adjudicated and classified consistently and accurately by a panel of clinical experts, removing potential bias from trial outcome assessments. By formalizing and expanding these structures under Prof. Haverkamp's guidance, SCIRENT is reinforcing its commitment to the highest standards of patient protection and scientific validity, aligning with rigorous guidelines set by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

"We are very pleased to welcome such an experienced and internationally respected expert to SCIRENT," commented Prof. Hans-Dirk Düngen. "Prof. Haverkamp's outstanding scientific background and deep expertise in electrophysiology and drug safety will significantly strengthen our medical capabilities and support the continued expansion of our services."

A Career Defined by Scientific Excellence

Prof. Haverkamp brings a formidable academic and clinical legacy to his new role. A board-certified specialist in internal medicine and cardiology, his career is marked by leadership positions and groundbreaking research. Before his long tenure at Charité – Universitätsmedizin Berlin, where he led the electrophysiology unit for years, he headed the same department at the University Hospital Münster.

His scientific achievements are documented in over 420 peer-reviewed publications in leading cardiovascular journals, with some databases counting over 600 publications and more than 22,000 citations. This vast body of work covers a wide spectrum of cardiovascular medicine, including internationally recognized expertise in acquired and inherited arrhythmias, heart failure, and cardiogenetics. His extensive experience as a principal investigator in numerous international clinical trials has given him firsthand knowledge of the operational and ethical complexities of drug and device development, making him uniquely qualified to lead SCIRENT's medical oversight.

Embracing the AI Revolution in Cardiac Research

Beyond his foundational expertise, Prof. Haverkamp is at the forefront of integrating next-generation technology into medicine. In recent years, his research has increasingly focused on the application of artificial intelligence in cardiac diagnostics, a field poised to revolutionize patient care. AI-enhanced electrocardiography (ECG), for instance, can identify subtle patterns invisible to the human eye, enabling earlier diagnosis of conditions like atrial fibrillation or the prediction of left ventricular dysfunction.

This forward-looking expertise is a critical asset for SCIRENT. The clinical research industry is rapidly adopting AI to analyze massive datasets, improve the efficiency of clinical trials, and enhance patient monitoring through wearable technology. By bringing in a leader who is not only familiar with but actively contributing to AI's role in cardiology, SCIRENT positions itself to offer more sophisticated, efficient, and insightful clinical trial services. This integration of AI is expected to enhance everything from patient recruitment to the real-time monitoring of drug safety, particularly in assessing a drug's effect on cardiac rhythms.

With this appointment, SCIRENT, a company founded in 2012 with a vision to advance cardiovascular therapies, is making a clear statement about its future direction. The decision to install a scientific luminary with deep expertise in both classical cardiology and emerging AI technologies underscores a strategy focused on scientific rigor, unparalleled safety, and technological innovation. This combination aims to not only enhance SCIRENT's competitive position in the specialized cardiovascular CRO market but also to contribute meaningfully to the development of safer, more effective treatments for patients with heart disease worldwide.